| Literature DB >> 33779841 |
Poonam Bhatia1,2, Jennifer Heim1, Patricia Cornejo2, Lauren Kane1,3, Jason Santiago1, Michael C Kruer4,5,6.
Abstract
Opsoclonus-myoclonus-ataxia syndrome is a rare neuroimmunologic disorder typically presenting in previously healthy infants and toddlers. It is characterized by a clinical triad of (1) erratic saccadic intrusions; (2) myoclonus and/or ataxia; (3) behavioral features, typified by developmental plateauing, irritability and insomnia. About half of cases are associated with an underlying neuroblastoma and diagnostic imaging is essential once OMAS is suspected. A thorough workup, including serum, urine, and cerebrospinal fluid studies is critical to identify underlying biomarkers of OMAS itself or neuroblastoma. Historically, many children had relatively poor long-term outcomes, with residual neurologic and/or neuropsychiatry sequelae typical. More recent concepts have emphasized combined immunotherapy regimens that offer hope for better outcomes in children with this remarkable, challenging disease.Entities:
Keywords: Movement disorders; Neuroimmunology; Opsoclonus–myoclonus–ataxia; Pediatric
Mesh:
Year: 2021 PMID: 33779841 DOI: 10.1007/s00415-021-10536-3
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849